Stockscreener 앱 받기
198.71
0.84%
-1.69
전일 마감가:
$200.40
열려 있는:
$199.5
하루 거래량:
4.06M
Relative Volume:
1.95
시가총액:
$59.07B
수익:
$20.64B
순이익/손실:
$1.73B
주가수익비율:
33.01
EPS:
6.02
순현금흐름:
$2.94B
1주 성능:
-0.21%
1개월 성능:
-12.78%
6개월 성능:
-17.32%
1년 성능:
-14.43%
1일 변동 폭
$198.40
$201.28
1주일 범위
$196.57
$206.78
52주 변동 폭
$193.03
$251.99
벡톤 디킨슨 Stock (BDX) Company Profile
명칭
Becton Dickinson Co
전화
(201) 847-6800
주소
ONE BECTON DR, FRANKLIN LAKES
BDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
198.71 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ISRG
Intuitive Surgical Inc
|
482.74 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
ALC
Alcon Inc
|
92.54 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
212.91 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
79.51 | 15.75B | 3.90B | 392.30M | 288.10M | 1.95 |
벡톤 디킨슨 Stock (BDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-05-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-12-12 | 업그레이드 | Citigroup | Sell → Neutral |
| 2022-07-11 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-06-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | 재개 | Raymond James | Mkt Perform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2021-12-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-25 | 개시 | Barclays | Equal Weight |
| 2020-12-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-06-01 | 재개 | Goldman | Buy |
| 2020-03-05 | 개시 | Citigroup | Neutral |
| 2020-02-07 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-02-07 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-01-08 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-05-13 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-12-07 | 개시 | Deutsche Bank | Buy |
| 2018-10-16 | 개시 | Barclays | Equal Weight |
| 2018-06-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-04-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-01-19 | 재개 | BofA/Merrill | Buy |
| 2018-01-05 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-01-05 | 개시 | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2017-12-29 | 재확인 | Deutsche Bank | Buy |
모두보기
벡톤 디킨슨 주식(BDX)의 최신 뉴스
Is Becton, Dickinson and Company (BDX) the Best Dividend Monarch to Invest in Now? - Insider Monkey
Is Becton Dickinson Gaining or Losing Market Support? - Benzinga
Global In-Vitro Diagnostics Market Predicted to Surpass the USD 90 Billion Mark by 2032 | DelveInsight - GlobeNewswire Inc.
Becton, Dickinson and Co. : Leading Industry Analyst Amit Bhalla Joins BD as Vice President, Global Strategy and Development - MarketScreener
Becton Dickinson in talks with Thermo Fisher, Danaher to divest life sciences unit, FT reports - MSN
Barclays Has Lowered Expectations for Becton, Dickinson and Company (NYSE:BDX) Stock Price - MarketBeat
Retired truck driver contends emissions from ethylene oxide caused his cancer - AJC.com
BD to acquire Bard - The Covington News
Becton, Dickinson and Co. : BD Appoints Christopher Reidy as Chief Financial Officer - MarketScreener
Becton Dickinson EVP Michael Garrison sells $94,497 in stock - Investing.com Australia
Becton Dickinson EVP Michael Garrison sells $94,497 in stock By Investing.com - Investing.com Canada
Becton Dickinson and : BD Receives FDA 510(k) Clearance for Advanced Microbiology Solution - MarketScreener
Becton Dickinson's SWOT analysis: med tech giant's stock poised for growth - Investing.com
BD Seeks Potential Buyers for Life Sciences Business Division - Yahoo Finance
Citigroup Adjusts Becton Dickinson and Co. Price Target to $270 From $275, Maintains Buy Rating - MarketScreener
Becton, Dickinson Becomes Oversold - Nasdaq
Should You be Confident in Becton, Dickinson and Company’s (BDX) Ability to Deliver Long-Term Returns? - Yahoo
BD reports pay increases for some execs, decreases for others - Medical Design & Outsourcing
BD to Announce Financial Results for its Second Quarter of Fiscal 2025 - Quantisnow
Vascular Access Device Market Growth is Driven by Ongoing Research and Development in the Industry, Key Players -Becton, Dickinson and Company, - Global Banking | Finance | Review
Report: BD is in talks with competitors to sell Life Sciences biz - MassDevice
Becton Dickinson in talks with Thermo Fisher, Danaher to divest life sciences unit, FT reports - MarketScreener
Becton Dickinson in talks to divest life sciences unit, FT reports - MarketScreener
Becton Dickinson In Talks With Rivals Over Divesting Life Sciences Unit- FT - MarketScreener
Becton Dickinson in talks with rivals over divesting life sciences unit - Financial Times
BD Named One of America's Most Innovative Companies by Fortune - Quantisnow
Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline - Seeking Alpha
Here’s What Positions Becton, Dickinson and Company (BDX) Favorably in the Health Care Sector - Yahoo Finance
BD Names Gregory J. Hayes to Board of Directors :: Becton, Dickinson and Company (BDX) - Becton Dickinson
BD Names Gregory J. Hayes to Board of Directors - Quantisnow
BD Names Gregory J. Hayes to Board of Directors – Company Announcement - Financial Times
Goldman Sachs Adjusts PT on Becton Dickinson and Co. to $256 From $253, Keeps Buy Rating - Marketscreener.com
Goldman Sachs Adjusts PT to Becton Dickinson and Co. to $256 From $253, Keeps Buy Rating - MarketScreener
Was Jim Cramer Right About Becton, Dickinson and Company (BDX)? - Insider Monkey
Insider Sell: Richard Byrd Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus.com
FDA tags Becton, Dickinson and Company infusion software recall as Class I - Yahoo Finance
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Becton Dickinson and : BD Announces Results for 2019 Second Fiscal Quarter; Updates Fiscal 2019 Guidance - MarketScreener
Becton, Dickinson Treats First Breast Revision Patient in GalaFlex Lite Scaffold Trial -March 20, 2025 at 07:56 am EDT - MarketScreener
BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery - Quantisnow
Becton, Dickinson and Company Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE? Scaffold in Breast Implant Revision Surgery - Marketscreener.com
Correction: Software for Alaris Systems Manager and CCE Adapter - fda.gov
Becton Dickinson EVP Richard Byrd sells $105,570 in stock By Investing.com - Investing.com Australia
Becton Dickinson EVP Richard Byrd sells $105,570 in stock - Investing.com
SEC Form 144 filed by Becton Dickinson and Company - Quantisnow
Here's Why Becton Dickinson (BDX) is a Strong Momentum Stock - Yahoo Finance
벡톤 디킨슨 (BDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
3.46%
자본화:
|
볼륨(24시간):